Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTS-CC 02 adjuvant SOX versus UFT/LV in stage IIIb colorectal cancer
jRCTs031180351Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Apr 2010
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tegafur, oxaliplatin, tegafur + uracil and folinic acid in colorectal cancer (CRC) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Disease-free survival. Started Apr 2010; status: completed.
02
Drugs
tegafuroxaliplatintegafur + uracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs031180351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180351.